Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Argus Health
Accenture
Chubb
UBS
Baxter
Medtronic
Chinese Patent Office
Harvard Business School
Boehringer Ingelheim

Generated: October 21, 2017

DrugPatentWatch Database Preview

AMBIEN Drug Profile

« Back to Dashboard

What is the patent landscape for Ambien, and when can generic versions of Ambien launch?

Ambien is a drug marketed by Sanofi Aventis Us and is included in two NDAs. There is one patent protecting this drug and two Paragraph IV challenges.

The generic ingredient in AMBIEN is zolpidem tartrate. There are thirty-one drug master file entries for this compound. Sixty-six suppliers are listed for this compound. Additional details are available on the zolpidem tartrate profile page.

Summary for Tradename: AMBIEN

US Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: see list5
Bulk Api Vendors: see list46
Clinical Trials: see list43
Patent Applications: see list617
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:AMBIEN at DailyMed

Pharmacology for Tradename: AMBIEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
AMBIEN
zolpidem tartrate
TABLET;ORAL019908-001Dec 16, 1992ABRXYesNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
AMBIEN CR
zolpidem tartrate
TABLET, EXTENDED RELEASE;ORAL021774-001Sep 2, 2005ABRXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis Us
AMBIEN
zolpidem tartrate
TABLET;ORAL019908-002Dec 16, 1992ABRXYesYes► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
AMBIEN CR
zolpidem tartrate
TABLET, EXTENDED RELEASE;ORAL021774-002Sep 2, 2005ABRXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: AMBIEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
AMBIEN
zolpidem tartrate
TABLET;ORAL019908-001Dec 16, 1992► Subscribe► Subscribe
Sanofi Aventis Us
AMBIEN
zolpidem tartrate
TABLET;ORAL019908-002Dec 16, 1992► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for AMBIEN

Drugname Dosage Strength RLD Submissiondate
zolpidem tartrateExtended-release Tablets6.25 mgAmbien CR2/24/2006
zolpidem tartrateExtended-release Tablets12.5 mgAmbien CR1/19/2006
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Cantor Fitzgerald
Julphar
Cipla
Argus Health
Federal Trade Commission
Johnson and Johnson
QuintilesIMS
Moodys
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot